Eli Lilly says new GLP-1 weight loss pill could reach market in 2026

Pharma company GSK has secured a $370 million settlement in a U.S. patent lawsuit and will also get a 1% royalty on future U.S. sales of certain mRNA vaccines—including flu and Covid-19 shots—produced by BioNTech and Pfizer.

Editor’s Note: This is a big win for GSK, not just because of the hefty payout but also because it ensures a steady stream of revenue from cutting-edge vaccines. For the industry, it highlights how valuable patent rights are, especially in the fast-growing mRNA vaccine space. If you're invested in pharma or healthcare, this kind of deal could signal more legal battles—and payouts—ahead.

Two mothers who faced challenges with breastfeeding credit a peer support group for helping them overcome their struggles and successfully nurse their babies.

Editor’s Note: Breastfeeding can be tough, and many new mums feel isolated when things don’t go as planned. This story highlights how community support can make a real difference, offering hope and practical help to parents navigating similar challenges. It’s a reminder that no one has to go it alone.

Tom Parker, a fisherman, was saved from sepsis after receiving prompt treatment at a walk-in harbour health clinic when he broke his fibula at sea. The article highlights how these specialized clinics—70 of which exist—could revolutionize healthcare delivery in the NHS by providing accessible, targeted care for high-risk workers like fishermen.

Editor’s Note: This story matters because it showcases a practical, life-saving solution for workers in dangerous professions, while also hinting at how similar models could improve the broader NHS system. It’s a hopeful example of innovation meeting urgent need.

Eli Lilly is making progress on a new weight loss pill that uses the same GLP-1 technology as its popular injections. While the pill version doesn’t work as well for weight loss as the shots, it could still be a game-changer for patients who prefer oral medication. The company plans to seek FDA approval by year-end, with hopes of hitting the market by 2026.

Editor’s Note: Weight loss drugs like Ozempic and Mounjaro have been huge, but they require injections—which isn’t ideal for everyone. A pill version could make these treatments more accessible and convenient, even if the results aren’t quite as dramatic. This could open up options for millions of people struggling with obesity, making it a big deal in the healthcare world.

This article provides a quick rundown of the latest updates and discussions in the health care sector, focusing on major players like Merck, Sandoz, and Bayer. It’s part of a regular market analysis series, offering insights into how these companies are performing and what trends might be shaping the industry.